首页 > 最新文献

Casopis lekaru ceskych最新文献

英文 中文
Diabetic foot attack. 糖尿病足发作
Q4 Medicine Pub Date : 2024-01-01
Milan Flekač

Diabetic foot attack is an acute manifestation of diabetic foot syndrome that requires rapid diagnosis and early initiation of complex therapy based on multidisciplinary team cooperation to save the affected limb. The term "attack" evokes the need for a rapid reaction as for "heart attack". Patients with diabetes mellitus and acute manifestations of diabetic foot syndrome have high risk for amputation of the lower limb, which is associated with higher morbidity and mortality. Complex therapy includes systemic antibiotic therapy, surgical debridement of ulceration, revascularization in the case of proven lower limb ischemia and an individualized offloading. Without the subsequent outpatient podiatric follow-up, the risk of recurrence increases significantly.

糖尿病足发作是糖尿病足综合征的一种急性表现,需要快速诊断,并在多学科团队合作的基础上尽早启动复杂的治疗,以挽救患肢。发作 "一词让人联想到需要像 "心脏病发作 "一样做出快速反应。糖尿病患者和有糖尿病足综合征急性表现的患者下肢截肢的风险很高,这与较高的发病率和死亡率有关。复杂的治疗包括全身抗生素治疗、手术清创溃疡、在证实下肢缺血的情况下进行血管重建以及个性化的负重治疗。如果没有后续的足病门诊随访,复发的风险会大大增加。
{"title":"Diabetic foot attack.","authors":"Milan Flekač","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Diabetic foot attack is an acute manifestation of diabetic foot syndrome that requires rapid diagnosis and early initiation of complex therapy based on multidisciplinary team cooperation to save the affected limb. The term \"attack\" evokes the need for a rapid reaction as for \"heart attack\". Patients with diabetes mellitus and acute manifestations of diabetic foot syndrome have high risk for amputation of the lower limb, which is associated with higher morbidity and mortality. Complex therapy includes systemic antibiotic therapy, surgical debridement of ulceration, revascularization in the case of proven lower limb ischemia and an individualized offloading. Without the subsequent outpatient podiatric follow-up, the risk of recurrence increases significantly.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 5","pages":"194-196"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roma people in the Czech Republic and cultural differences in health and health care. 捷克共和国的罗姆人与健康和医疗保健方面的文化差异。
Q4 Medicine Pub Date : 2024-01-01
Helena Hnilicová

From anthropometrics point of view, the Roma have retained a distinct individuality and thus differ from the majority population. They are also distinguished by cultural differences, which are reflected in the concept of health and health care consumption. The available data show socially and culturally determined health inequalities and disadvantages of the Roma compared to the majority population, which do not change in the long term. Among others, the low level of cultural competence and sensitivity of health professionals to the needs of minorities and specifically to the Roma ethnicity also plays a role. The article describes health-relevant cultural differences in the context of Roma culture and way of life of the Czech Roma and outlines some of the barriers faced by Roma in healthcare.

从人体测量学的角度来看,罗姆人保留了鲜明的个性,因此与大多数人口不同。他们还因文化差异而与众不同,这种差异反映在健康和保健消费观念上。现有数据表明,与大多数人口相比,罗姆人在健康方面的不平等和劣势是由社会和文化决定的,而且长期不会改变。其中,医疗专业人员对少数民族,特别是罗姆族的需求的文化能力和敏感度较低也是一个原因。文章介绍了罗姆文化和捷克罗姆人生活方式背景下与健康相关的文化差异,并概述了罗姆人在医疗保健方面面临的一些障碍。
{"title":"Roma people in the Czech Republic and cultural differences in health and health care.","authors":"Helena Hnilicová","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>From anthropometrics point of view, the Roma have retained a distinct individuality and thus differ from the majority population. They are also distinguished by cultural differences, which are reflected in the concept of health and health care consumption. The available data show socially and culturally determined health inequalities and disadvantages of the Roma compared to the majority population, which do not change in the long term. Among others, the low level of cultural competence and sensitivity of health professionals to the needs of minorities and specifically to the Roma ethnicity also plays a role. The article describes health-relevant cultural differences in the context of Roma culture and way of life of the Czech Roma and outlines some of the barriers faced by Roma in healthcare.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 5","pages":"203-208"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal impairment in monoclonal gammopathies and multiple myeloma. 单克隆丙种球蛋白病和多发性骨髓瘤的肾功能损害。
Q4 Medicine Pub Date : 2024-01-01
Romana Ryšavá

The incidence of monoclonal gammopathy (MG) increases with age. In individuals over 80 years of age, we can diagnose the presence of monoclonal immunoglobulin (MIg) in up to 10 % of cases. Not only malignant diseases such as multiple myeloma (MM), but also benign forms such as MGUS (monoclonal gammopathy of undetermined significance) can lead to renal involvement. The light chains of immunoglobulins (LC) are the most damaging to the kidneys, as they are freely filtered into the urine due to their molecular weight. Detection of MIg relies mainly on a combination of immunofixation electrophoresis of serum (IELFO) and urine and determination of free light chains (FLC) of kappa and lambda and their ratio (κ/λ) in serum. The combination of these tests will detect the presence of MIg with 99 % sensitivity. Renal damage in MG may be caused by direct deposition of MIg in the glomeruli (e.g. AL amyloidosis, LC deposition disease) or tubules (in the distal tubule as a myeloma kidney or in the proximal tubule as Fanconi syndrome or proximal tubulopathy). Typical urinary findings in these diseases are moderate or severe proteinuria or nephrotic syndrome. Acute kidney injury (AKI) can be expected especially when serum FLC is >500 mg/l. Renal biopsy is crucial to establish an accurate diagnosis and thus initiate the correct treatment. Treatment of these types of renal damage involves the same treatment regimens used in the treatment of MM, including proteasome inhibitors or daratumumab.

单克隆丙种球蛋白病(MG)的发病率随着年龄的增长而增加。在 80 岁以上的人群中,我们可以诊断出单克隆免疫球蛋白(MIg)存在的比例高达 10%。不仅多发性骨髓瘤(MM)等恶性疾病,MGUS(意义未定的单克隆免疫球蛋白病)等良性疾病也会导致肾脏受累。免疫球蛋白(LC)的轻链对肾脏的损害最大,因为它们的分子量可以自由地滤入尿液。MIg的检测主要依靠血清(IELFO)和尿液的免疫固定电泳以及血清中卡帕和λ游离轻链(FLC)及其比值(κ/λ)的测定。结合这些检测方法可检测出是否存在 MG,灵敏度高达 99%。MG的肾损伤可能是由于MIg直接沉积在肾小球(如AL淀粉样变性、LC沉积病)或肾小管(在远端肾小管如骨髓瘤肾,或在近端肾小管如范可尼综合征或近端肾小管病变)。这些疾病的典型尿检结果是中度或重度蛋白尿或肾病综合征。特别是当血清FLC达到500毫克/升时,急性肾损伤(AKI)可能会出现。肾活检对于确定准确诊断并开始正确治疗至关重要。治疗这些类型的肾损伤需要采用与治疗 MM 相同的治疗方案,包括蛋白酶体抑制剂或达拉单抗。
{"title":"Renal impairment in monoclonal gammopathies and multiple myeloma.","authors":"Romana Ryšavá","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The incidence of monoclonal gammopathy (MG) increases with age. In individuals over 80 years of age, we can diagnose the presence of monoclonal immunoglobulin (MIg) in up to 10 % of cases. Not only malignant diseases such as multiple myeloma (MM), but also benign forms such as MGUS (monoclonal gammopathy of undetermined significance) can lead to renal involvement. The light chains of immunoglobulins (LC) are the most damaging to the kidneys, as they are freely filtered into the urine due to their molecular weight. Detection of MIg relies mainly on a combination of immunofixation electrophoresis of serum (IELFO) and urine and determination of free light chains (FLC) of kappa and lambda and their ratio (κ/λ) in serum. The combination of these tests will detect the presence of MIg with 99 % sensitivity. Renal damage in MG may be caused by direct deposition of MIg in the glomeruli (e.g. AL amyloidosis, LC deposition disease) or tubules (in the distal tubule as a myeloma kidney or in the proximal tubule as Fanconi syndrome or proximal tubulopathy). Typical urinary findings in these diseases are moderate or severe proteinuria or nephrotic syndrome. Acute kidney injury (AKI) can be expected especially when serum FLC is &gt;500 mg/l. Renal biopsy is crucial to establish an accurate diagnosis and thus initiate the correct treatment. Treatment of these types of renal damage involves the same treatment regimens used in the treatment of MM, including proteasome inhibitors or daratumumab.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 3","pages":"98-105"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in medicine and healthcare: Opportunity and/or threat. 人工智能在医疗和保健领域的应用:机遇和/或威胁。
Q4 Medicine Pub Date : 2024-01-01
Lenka Lhotská

The aim of the article to present the development of artificial intelligence (AI) methods and their applications in medicine and health care. Current technological development contributes to generation of large volumes of data that cannot be evaluated only manually. We describe the process of patient care and its individual parts that can be supported by technology and data analysis methods. There are many successful applications that help in the decision support process, in processing complex multidimensional heterogeneous and/or long-term data. On the other side, failures appear in AI methods applications. In recent years, deep learning became very popular and to a certain extend it delivered promising results. However, it has certain flaws that might lead to misclassification. The correct methodological steps in design and implementation of selected methods to data processing are briefly presented.

本文旨在介绍人工智能(AI)方法的发展及其在医疗和保健领域的应用。当前的技术发展促进了大量数据的产生,而这些数据仅靠人工是无法评估的。我们描述了病人护理过程及其各个环节,这些都可以通过技术和数据分析方法来支持。在处理复杂的多维异构数据和/或长期数据的决策支持过程中,有许多成功的应用。另一方面,人工智能方法的应用也出现了失败。近年来,深度学习变得非常流行,并在一定程度上取得了可喜的成果。然而,它也存在一些缺陷,可能会导致错误分类。本文简要介绍了设计和实施选定数据处理方法的正确方法步骤。
{"title":"Artificial intelligence in medicine and healthcare: Opportunity and/or threat.","authors":"Lenka Lhotská","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of the article to present the development of artificial intelligence (AI) methods and their applications in medicine and health care. Current technological development contributes to generation of large volumes of data that cannot be evaluated only manually. We describe the process of patient care and its individual parts that can be supported by technology and data analysis methods. There are many successful applications that help in the decision support process, in processing complex multidimensional heterogeneous and/or long-term data. On the other side, failures appear in AI methods applications. In recent years, deep learning became very popular and to a certain extend it delivered promising results. However, it has certain flaws that might lead to misclassification. The correct methodological steps in design and implementation of selected methods to data processing are briefly presented.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"162 7-8","pages":"275-278"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19: to vaccinate or not to vaccinate - that is the question. COVID-19:接种还是不接种--这是一个问题。
Q4 Medicine Pub Date : 2024-01-01
Jiří Městecký, Milan Raška

SARS-CoV-2 is a virus which infects the respiratory tract and may cause severe, occasionally life-threatening disease COVID-19. In more than 5% of symptomatic patients the infection is associated with post-acute symptoms. The initial contact of the virus with the immune system of the nasopharynx and oropharynx induces a mucosal immune response manifested by the production of secretory IgA (sIgA) antibodies which may contribute to the restriction of the infection to the upper respiratory tract and an asymptomatic or clinically mild disease. The current systemically administered vaccines protected against the severe COVID-19 infection and its post-acute sequelae. However, they do not induce antibodies in mucosal secretions in SARS-CoV-2-naive individuals. In contrast, in those who previously experienced mucosal infection, systemically administered vaccines may stimulate sIgA production. The clinical benefit of systemic vaccination convincingly documented in tens of millions of individuals overshadows the rare, sometimes controversial reports of complications encountered after vaccination. The inability of current SARS-CoV-2 vaccines to induce mucosal immune responses and to prevent the spreading of the virus by external secretions demonstrates the mutual independence of mucosal and systemic compartments of the immune system, and thus emphasizes need for the development of vaccines inducing protective immune responses in both compartments.

SARS-CoV-2 是一种感染呼吸道的病毒,可引起严重的、偶尔危及生命的 COVID-19 疾病。在 5%以上有症状的患者中,感染后会出现急性症状。病毒与鼻咽部和口咽部免疫系统的初次接触会诱发粘膜免疫反应,表现为分泌型 IgA(sIgA)抗体的产生,这可能导致感染局限于上呼吸道和无症状或临床症状轻微的疾病。目前全身接种的疫苗可预防严重的 COVID-19 感染及其急性后遗症。然而,它们并不能在 SARS-CoV-2 免疫者的粘膜分泌物中诱导抗体。相反,对于那些曾经历过粘膜感染的人来说,全身接种疫苗可刺激 sIgA 的产生。数以千万计的人接种了全身性疫苗,其临床益处令人信服,但接种疫苗后出现并发症的报道却很少见,有时甚至引起争议。目前的 SARS-CoV-2 疫苗无法诱导粘膜免疫反应,也无法防止病毒通过外部分泌物传播,这表明免疫系统的粘膜区和全身区是相互独立的,因此强调需要开发能诱导这两个区产生保护性免疫反应的疫苗。
{"title":"COVID-19: to vaccinate or not to vaccinate - that is the question.","authors":"Jiří Městecký, Milan Raška","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>SARS-CoV-2 is a virus which infects the respiratory tract and may cause severe, occasionally life-threatening disease COVID-19. In more than 5% of symptomatic patients the infection is associated with post-acute symptoms. The initial contact of the virus with the immune system of the nasopharynx and oropharynx induces a mucosal immune response manifested by the production of secretory IgA (sIgA) antibodies which may contribute to the restriction of the infection to the upper respiratory tract and an asymptomatic or clinically mild disease. The current systemically administered vaccines protected against the severe COVID-19 infection and its post-acute sequelae. However, they do not induce antibodies in mucosal secretions in SARS-CoV-2-naive individuals. In contrast, in those who previously experienced mucosal infection, systemically administered vaccines may stimulate sIgA production. The clinical benefit of systemic vaccination convincingly documented in tens of millions of individuals overshadows the rare, sometimes controversial reports of complications encountered after vaccination. The inability of current SARS-CoV-2 vaccines to induce mucosal immune responses and to prevent the spreading of the virus by external secretions demonstrates the mutual independence of mucosal and systemic compartments of the immune system, and thus emphasizes need for the development of vaccines inducing protective immune responses in both compartments.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 4","pages":"131-136"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Je obezita a malnutrice u geriatrických pacientů problémem z hlediska dávkování analgetik? 老年病人的肥胖和营养不良是否会影响镇痛剂的剂量?
Q4 Medicine Pub Date : 2024-01-01
Eliška Dvořáčková

Both obesity and malnutrition in the elderly population are raising concerns. As majority of pharmacokinetic data are obtained from subjects with a healthy weight range in productive age, administration of correct dosing of drugs to obese elderly patients is quite challenging. All phases of the pharmacokinetics of drugs (absorption, distribution, metabolism and elimination) are potentially affected by the effect of aging but also by obesity or malnutrition. These changes are often potentiated in the case of a combination of obesity and older age. The problem is also that not all drugs are affected in the same way, therefore it is necessary to know the influence of age and obesity on the kinetics of the particular substance being assessed. 50% of seniors suffer from pain at home and up to 80% during hospitalization. In addition to general knowledge about the effect of age but also obesity and malnutrition on the kinetics of drugs, this overview presents the pharmacokinetic changes of analgesics caused by both obesity and malnutrition.

老年人群中的肥胖和营养不良问题正引起人们的关注。由于大多数药代动力学数据都是从生产年龄段体重在健康范围内的受试者身上获得的,因此对肥胖的老年患者进行正确的药物剂量管理具有相当大的挑战性。药物代谢动力学的所有阶段(吸收、分布、代谢和消除)都可能受到衰老的影响,也可能受到肥胖或营养不良的影响。在肥胖和高龄并存的情况下,这些变化往往会加剧。问题还在于,并非所有药物都会受到同样的影响,因此有必要了解年龄和肥胖对所评估的特定物质的动力学的影响。50% 的老年人在家中会感到疼痛,住院期间则高达 80%。除了关于年龄、肥胖和营养不良对药物动力学影响的一般知识外,本概述还介绍了肥胖和营养不良引起的镇痛药的药代动力学变化。
{"title":"Je obezita a malnutrice u geriatrických pacientů problémem z hlediska dávkování analgetik?","authors":"Eliška Dvořáčková","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Both obesity and malnutrition in the elderly population are raising concerns. As majority of pharmacokinetic data are obtained from subjects with a healthy weight range in productive age, administration of correct dosing of drugs to obese elderly patients is quite challenging. All phases of the pharmacokinetics of drugs (absorption, distribution, metabolism and elimination) are potentially affected by the effect of aging but also by obesity or malnutrition. These changes are often potentiated in the case of a combination of obesity and older age. The problem is also that not all drugs are affected in the same way, therefore it is necessary to know the influence of age and obesity on the kinetics of the particular substance being assessed. 50% of seniors suffer from pain at home and up to 80% during hospitalization. In addition to general knowledge about the effect of age but also obesity and malnutrition on the kinetics of drugs, this overview presents the pharmacokinetic changes of analgesics caused by both obesity and malnutrition.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 1","pages":"32-37"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polypragmazie a jak jí předcházet. 多发性瘫痪和如何预防多发性瘫痪。
Q4 Medicine Pub Date : 2024-01-01
Jan Miroslav Hartinger, Daniel Laurus Bobek

Polypharmacy is currently a serious problem that causes decrease in adherence and increased number of hospitalizations and mortality. WHO addresses polypharmacy in the Medication Without Harm campaign. Other initiatives that deal with polypharmacy are the International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP) and Choosing Wisely campaign. The correct approach to address polypharmacy consists of its prevention, i.e. not prescribing inappropriate or unnecessary medication and providing clear timeframe for medication that should not be continued life-long. Further on we should actively seek patients suffering from polypharmacy and intervene it by deprescription. Correctly provided deprescription can be done by means of various tools beginning from simple lists of inappropriate drugs (Beers criteria, STOPP/START) to more comprehensive approaches that evaluate the importance of each particular drug in patient's medication list and help to identify the least important ones that are candidates for deprescription (Medication Appropriateness Index, Good Palliative Geriatric Practice Algorithm and others). When evaluating the appropriateness of pharmacotherapy, we always check if the treatment aim is achieved, if the indication persists, appropriateness of dosing and if the patient understands the pharmacotherapeutical regimen. By this approach we try to eliminate the pharmacotherapy with very low or no benefit for particular patient. Clinical pharmacologist or pharmacist can significantly help with this time-consuming process.

目前,多重用药是一个严重问题,它导致用药依从性下降,住院人数和死亡率增加。世卫组织在 "无伤害用药 "运动中处理了多药滥用问题。其他应对多重用药的倡议包括国际减少不当用药和多重用药小组(IGRIMUP)和明智选择运动。解决多重用药问题的正确方法包括预防,即不开具不适当或不必要的药物,并为不应终身服用的药物提供明确的时限。此外,我们应积极寻找多重用药的患者,并通过停药进行干预。正确的停药可以通过各种工具来实现,从简单的不适当药物清单(比尔斯标准、STOPP/START)到更全面的方法,即评估患者用药清单中每种特定药物的重要性,并帮助确定哪些药物最不重要,可以停用(用药适当性指数、良好的老年姑息治疗实践算法等)。在评估药物治疗的适当性时,我们总是要检查治疗目的是否达到、适应症是否持续、剂量是否适当以及患者是否理解药物治疗方案。通过这种方法,我们会尽量淘汰对特定患者疗效极差或无益的药物疗法。临床药剂师或药剂师可以在这一耗时的过程中提供重要帮助。
{"title":"Polypragmazie a jak jí předcházet.","authors":"Jan Miroslav Hartinger, Daniel Laurus Bobek","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Polypharmacy is currently a serious problem that causes decrease in adherence and increased number of hospitalizations and mortality. WHO addresses polypharmacy in the Medication Without Harm campaign. Other initiatives that deal with polypharmacy are the International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP) and Choosing Wisely campaign. The correct approach to address polypharmacy consists of its prevention, i.e. not prescribing inappropriate or unnecessary medication and providing clear timeframe for medication that should not be continued life-long. Further on we should actively seek patients suffering from polypharmacy and intervene it by deprescription. Correctly provided deprescription can be done by means of various tools beginning from simple lists of inappropriate drugs (Beers criteria, STOPP/START) to more comprehensive approaches that evaluate the importance of each particular drug in patient's medication list and help to identify the least important ones that are candidates for deprescription (Medication Appropriateness Index, Good Palliative Geriatric Practice Algorithm and others). When evaluating the appropriateness of pharmacotherapy, we always check if the treatment aim is achieved, if the indication persists, appropriateness of dosing and if the patient understands the pharmacotherapeutical regimen. By this approach we try to eliminate the pharmacotherapy with very low or no benefit for particular patient. Clinical pharmacologist or pharmacist can significantly help with this time-consuming process.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 1","pages":"3-8"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large language models are changing landscape of academic publications. A positive transformation? 大型语言模型正在改变学术出版物的格局。积极的转变?
Q4 Medicine Pub Date : 2024-01-01
Martin Májovský, Martin Černý, David Netuka

The advent of large language models (LLMs) based on neural networks marks a significant shift in academic writing, particularly in medical sciences. These models, including OpenAI's GPT-4, Google's Bard, and Anthropic's Claude, enable more efficient text processing through transformer architecture and attention mechanisms. LLMs can generate coherent texts that are indistinguishable from human-written content. In medicine, they can contribute to the automation of literature reviews, data extraction, and hypothesis formulation. However, ethical concerns arise regarding the quality and integrity of scientific publications and the risk of generating misleading content. This article provides an overview of how LLMs are changing medical writing, the ethical dilemmas they bring, and the possibilities for detecting AI-generated text. It concludes with a focus on the potential future of LLMs in academic publishing and their impact on the medical community.

基于神经网络的大型语言模型(LLM)的出现标志着学术写作的重大转变,尤其是在医学科学领域。这些模型,包括 OpenAI 的 GPT-4、谷歌的 Bard 和 Anthropic 的 Claude,通过转换器架构和注意力机制实现了更高效的文本处理。LLM 可以生成与人类书写内容无异的连贯文本。在医学领域,它们有助于实现文献综述、数据提取和假设提出的自动化。然而,科学出版物的质量和完整性以及产生误导性内容的风险会引起道德方面的担忧。本文概述了 LLM 如何改变医学写作、其带来的伦理困境以及检测人工智能生成文本的可能性。最后,文章重点探讨了LLM在学术出版领域的潜在前景及其对医学界的影响。
{"title":"Large language models are changing landscape of academic publications. A positive transformation?","authors":"Martin Májovský, Martin Černý, David Netuka","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The advent of large language models (LLMs) based on neural networks marks a significant shift in academic writing, particularly in medical sciences. These models, including OpenAI's GPT-4, Google's Bard, and Anthropic's Claude, enable more efficient text processing through transformer architecture and attention mechanisms. LLMs can generate coherent texts that are indistinguishable from human-written content. In medicine, they can contribute to the automation of literature reviews, data extraction, and hypothesis formulation. However, ethical concerns arise regarding the quality and integrity of scientific publications and the risk of generating misleading content. This article provides an overview of how LLMs are changing medical writing, the ethical dilemmas they bring, and the possibilities for detecting AI-generated text. It concludes with a focus on the potential future of LLMs in academic publishing and their impact on the medical community.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"162 7-8","pages":"294-297"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence's contribution to early pulmonary lesion detection in chest X-rays: insights from two retrospective studies on a Czech population. 人工智能对胸部 X 射线早期肺部病变检测的贡献:两项针对捷克人群的回顾性研究的启示。
Q4 Medicine Pub Date : 2024-01-01
Martin Černý, Daniel Kvak, Daniel Schwarz, Hynek Mírka, Jakub Dandár

In recent years healthcare is undergoing significant changes due to technological innovations, with Artificial Intelligence (AI) being a key trend. Particularly in radiodiagnostics, according to studies, AI has the potential to enhance accuracy and efficiency. We focus on AI's role in diagnosing pulmonary lesions, which could indicate lung cancer, based on chest X-rays. Despite lower sensitivity in comparison to other methods like chest CT, due to its routine use, X-rays often provide the first detection of lung lesions. We present our deep learning-based solution aimed at improving lung lesion detection, especially during early-stage of illness. We then share results from our previous studies validating this model in two different clinical settings: a general hospital with low prevalence findings and a specialized oncology center. Based on a quantitative comparison with the conclusions of radiologists of different levels of experience, our model achieves high sensitivity, but lower specificity than comparing radiologists. In the context of clinical requirements and AI-assisted diagnostics, the experience and clinical reasoning of the doctor play a crucial role, therefore we currently lean more towards models with higher sensitivity over specificity. Even unlikely suspicions are presented to the doctor. Based on these results, it can be expected that in the future artificial intelligence will play a key role in the field of radiology as a supporting tool for evaluating specialists. To achieve this, it is necessary to solve not only technical but also medical and regulatory aspects. It is crucial to have access to quality and reliable information not only about the benefits but also about the limitations of machine learning and AI in medicine.

近年来,由于技术创新,医疗保健领域正在发生重大变化,其中人工智能(AI)是一个重要趋势。特别是在放射诊断方面,根据研究,人工智能有可能提高诊断的准确性和效率。我们重点关注人工智能在根据胸部 X 光片诊断肺部病变(可能预示肺癌)方面的作用。尽管与胸部 CT 等其他方法相比,X 射线的灵敏度较低,但由于其常规用途,X 射线往往能在第一时间发现肺部病变。我们介绍了基于深度学习的解决方案,旨在改进肺部病变检测,尤其是在疾病的早期阶段。然后,我们分享了之前在两种不同临床环境中验证该模型的研究结果:一家发病率较低的综合医院和一家专业肿瘤中心。通过与不同经验水平的放射科医生的结论进行定量比较,我们的模型具有较高的灵敏度,但特异性低于放射科医生。在临床要求和人工智能辅助诊断的背景下,医生的经验和临床推理起着至关重要的作用,因此我们目前更倾向于灵敏度高于特异性的模型。即使是不可能的疑点,也要向医生提出。基于这些结果,我们可以预见,人工智能作为评估专家的辅助工具,未来将在放射学领域发挥重要作用。要实现这一目标,不仅要解决技术方面的问题,还要解决医疗和监管方面的问题。关键是要获得高质量的可靠信息,不仅要了解机器学习和人工智能在医学中的益处,还要了解其局限性。
{"title":"Artificial intelligence's contribution to early pulmonary lesion detection in chest X-rays: insights from two retrospective studies on a Czech population.","authors":"Martin Černý, Daniel Kvak, Daniel Schwarz, Hynek Mírka, Jakub Dandár","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In recent years healthcare is undergoing significant changes due to technological innovations, with Artificial Intelligence (AI) being a key trend. Particularly in radiodiagnostics, according to studies, AI has the potential to enhance accuracy and efficiency. We focus on AI's role in diagnosing pulmonary lesions, which could indicate lung cancer, based on chest X-rays. Despite lower sensitivity in comparison to other methods like chest CT, due to its routine use, X-rays often provide the first detection of lung lesions. We present our deep learning-based solution aimed at improving lung lesion detection, especially during early-stage of illness. We then share results from our previous studies validating this model in two different clinical settings: a general hospital with low prevalence findings and a specialized oncology center. Based on a quantitative comparison with the conclusions of radiologists of different levels of experience, our model achieves high sensitivity, but lower specificity than comparing radiologists. In the context of clinical requirements and AI-assisted diagnostics, the experience and clinical reasoning of the doctor play a crucial role, therefore we currently lean more towards models with higher sensitivity over specificity. Even unlikely suspicions are presented to the doctor. Based on these results, it can be expected that in the future artificial intelligence will play a key role in the field of radiology as a supporting tool for evaluating specialists. To achieve this, it is necessary to solve not only technical but also medical and regulatory aspects. It is crucial to have access to quality and reliable information not only about the benefits but also about the limitations of machine learning and AI in medicine.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"162 7-8","pages":"283-289"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for postoperative pneumonia in patients after lung resection for non-small cell lung cancer - results of a cohort study. 非小细胞肺癌肺切除术后患者术后肺炎的风险因素--一项队列研究的结果。
Q4 Medicine Pub Date : 2024-01-01
Markéta Kepičová, Lubomír Tulinský, Adéla Kondé, Čestmír Neoral, Lubomír Martínek

Postoperative pneumonia is the most common complication in patients after lung resection for non-small cell lung cancer (NSCLC). The tolerable incidence of this complication ranges from 5 to 8 %. The aim of this study was to evaluate the influence of initial risk factors on the incidence of postoperative pneumonia in patients undergoing lung resection for NSCLC. A retrospective cohort study was conducted at the University Hospital Ostrava between January 1, 2016, and December 31, 2022. All adult patients who underwent pulmonary lobectomy for primary NSCLC during the study period were included in the study. A total of 350 patients were included in the study. The incidence of postoperative pneumonia was 10.9%. Analysis of baseline risk factors did not show a statistically significant association with the incidence of this complication. The only statistically significant finding was a longer hospital stay in patients with postoperative pneumonia. The risk of postoperative pneumonia in patients undergoing lung resection for non-small cell lung cancer cannot be clearly explained by the initial risk factors examined alone. The complex nature of this risk also requires a comprehensive approach to prevention, including both patient-centred measures and improved postoperative care.

术后肺炎是非小细胞肺癌(NSCLC)肺切除术后最常见的并发症。这种并发症的可耐受发生率为 5% 到 8%。本研究旨在评估初始风险因素对非小细胞肺癌肺切除术患者术后肺炎发生率的影响。奥斯特拉瓦大学医院在2016年1月1日至2022年12月31日期间开展了一项回顾性队列研究。在研究期间,所有因原发性 NSCLC 而接受肺叶切除术的成年患者均被纳入研究范围。研究共纳入了 350 名患者。术后肺炎的发生率为10.9%。对基线风险因素的分析表明,该并发症的发生率与基线风险因素并无统计学意义。唯一有统计学意义的发现是术后肺炎患者的住院时间更长。接受肺切除术的非小细胞肺癌患者术后肺炎的风险不能仅由最初研究的风险因素来明确解释。这种风险的复杂性还要求采取全面的预防方法,包括以患者为中心的措施和改善术后护理。
{"title":"Risk factors for postoperative pneumonia in patients after lung resection for non-small cell lung cancer - results of a cohort study.","authors":"Markéta Kepičová, Lubomír Tulinský, Adéla Kondé, Čestmír Neoral, Lubomír Martínek","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Postoperative pneumonia is the most common complication in patients after lung resection for non-small cell lung cancer (NSCLC). The tolerable incidence of this complication ranges from 5 to 8 %. The aim of this study was to evaluate the influence of initial risk factors on the incidence of postoperative pneumonia in patients undergoing lung resection for NSCLC. A retrospective cohort study was conducted at the University Hospital Ostrava between January 1, 2016, and December 31, 2022. All adult patients who underwent pulmonary lobectomy for primary NSCLC during the study period were included in the study. A total of 350 patients were included in the study. The incidence of postoperative pneumonia was 10.9%. Analysis of baseline risk factors did not show a statistically significant association with the incidence of this complication. The only statistically significant finding was a longer hospital stay in patients with postoperative pneumonia. The risk of postoperative pneumonia in patients undergoing lung resection for non-small cell lung cancer cannot be clearly explained by the initial risk factors examined alone. The complex nature of this risk also requires a comprehensive approach to prevention, including both patient-centred measures and improved postoperative care.</p>","PeriodicalId":9645,"journal":{"name":"Casopis lekaru ceskych","volume":"163 3","pages":"94-97"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Casopis lekaru ceskych
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1